Comparative Pharmacology
Head-to-head clinical analysis: GABITRIL versus PRIMIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABITRIL versus PRIMIDONE.
GABITRIL vs PRIMIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiagabine inhibits gamma-aminobutyric acid (GABA) reuptake into presynaptic neurons, thereby increasing synaptic GABA levels and enhancing inhibitory neurotransmission.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
Initial dose: 4 mg orally twice daily. Titrate by 4-8 mg/day every 2 weeks. Maximum dose: 56 mg/day in 2-4 divided doses.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
None Documented
None Documented
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
Terminal elimination half-life is 7–9 hours in healthy adults. In patients with hepatic impairment, half-life is prolonged (up to 12–24 hours) due to reduced clearance. No significant effect of renal impairment.
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Approximately 70% of an oral dose is excreted in feces, 25% in urine, and 5% in bile. Renal elimination of unchanged drug is minimal (<2%); most is eliminated as metabolites.
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Category C
Category D/X
Anticonvulsant
Anticonvulsant